Revolutionising Oncology Medicine: A Precision Approach that Cuts Costs and Boosts ROI

By Staff Writer

July 11, 2023

In a groundbreaking study published in Journal of Pharmaceutical Policy and Practice volume, an analysis was conducted on the R&D costs of oncology medicines. The analysis, based on data from company filings from 1997 to 2020, indicates that a precision approach to oncology medicine development using Companion Diagnostic (CDx) could significantly reduce costs and increase ROI.

Despite some missing data, primarily from larger pharmaceutical companies that have acquired smaller firms, the study still provides a robust picture of the R&D landscape. They found that the total R&D spend to develop an oncology medicine (inconsistent use of CDx) is $4432.1 m, a figure that is significantly reduced when a CDx-guided precision oncology approach is adopted.

While the World Health Organization (WHO) has called for more transparency in R&D costs, this study highlights the need for standardisation in reporting R&D spend. This is crucial for health systems to make well-informed decisions on healthcare policy and for the pharmaceutical industry to recover R&D costs and continue innovating.

Findings suggest that precision oncology medicines guided by CDx are not only less expensive to develop but also offer better value to stakeholders, including patients, payers, and the pharmaceutical industry. This approach not only reduces R&D spend but also accelerates the reimbursement process and requires a rethinking of market access strategies.

The implications are far-reaching, impacting drug discovery, market access, health outcomes, and industry policy. As the pharmaceutical industry realises the cost-effectiveness of precision oncology medicines, it presents challenges to ensure equitable treatment provision for all patients.

This study emphasises the need for a flexible CDx development framework to truly benefit patients and ensure that R&D spend in oncology medicine development is affordable to health systems. The industry should revisit the commercial model for precision medicines and their associated diagnostic/prognostic tests to capitalise on the benefits of precision medicine.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.